We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The POET II trial reports that stopping antibiotic treatment in patients with endocarditis once they are clinically stable shortens the treatment duration without excess risk of death or surgery, but triples the rates of relapse of endocarditis or bacteraemia. This response-guided strategy marks a genuine shift beyond the oral-antibiotic-switch paradigm from the POET trial, and the safety of the approach will depend on rigorous patient selection and close multidisciplinary follow-up.”
No takes yet. Share an insight, caveat, or question.
DeSimone et al. (2026) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: